TG Therapeutics Inc (TGTX)

4.65
NASDAQ : Health Care
Prev Close 4.70
Day Low/High 4.50 / 4.75
52 Wk Low/High 4.10 / 10.50
Avg Volume 386.30K
Exchange NASDAQ
Shares Outstanding 54.73M
Market Cap 257.24M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TG Therapeutics, Inc. To Present At The 2017 BIO CEO & Investor Conference

TG Therapeutics, Inc. To Present At The 2017 BIO CEO & Investor Conference

Presentation Scheduled for Monday, February 13, 2017 at 9:00am ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc.

TGTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017

TGTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc.

TG Therapeutics Enters Oversold Territory (TGTX)

TG Therapeutics Enters Oversold Territory (TGTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

TG Therapeutics, Inc. To Present At The 35th Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. To Present At The 35th Annual J.P. Morgan Healthcare Conference

Presentation Scheduled for Thursday, January 12, 2017 at 10:30am PST

TG Therapeutics, Inc. Announces Investigator Initiated Trial At The University Of Nebraska Medical Center To Study TGR-1202 In Combination With Ibrutinib In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma

TG Therapeutics, Inc. Announces Investigator Initiated Trial At The University Of Nebraska Medical Center To Study TGR-1202 In Combination With Ibrutinib In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma

Phase 2 trial of TGR-1202 plus ibrutinib designed to target B-cell receptor (BCR) pathway at multiple points in DLBCL patients relapsed from or ineligible for stem cell transplant

First Week of August 2017 Options Trading For TG Therapeutics (TGTX)

First Week of August 2017 Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics, Inc. Announces Publication Of Clinical Data From The Phase 2 Trial Of TG-1101 (ublituximab) In Combination With Ibrutinib In The British Journal Of Haematology

TG Therapeutics, Inc. Announces Publication Of Clinical Data From The Phase 2 Trial Of TG-1101 (ublituximab) In Combination With Ibrutinib In The British Journal Of Haematology

Combination treatment resulted in 95% ORR in patients with High-Risk CLL, the patient population being evaluated in the Phase 3 GENUINE Trial

TG Therapeutics, Inc. Announces That The GENUINE Phase 3 Study Has Reached Target Enrollment

TG Therapeutics, Inc. Announces That The GENUINE Phase 3 Study Has Reached Target Enrollment

Top-line data expected first half 2017

TG Therapeutics, Inc. Announces Preclinical Data Presentations For TGR-1202 At The 58th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Announces Preclinical Data Presentations For TGR-1202 At The 58th American Society Of Hematology Annual Meeting

Preclinical work may offer rationale for the differentiated activity and safety effects of TGR-1202

TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 58th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Recaps Schedule Of Data Presentations At The 58th American Society Of Hematology Annual Meeting

Investor Reception to be Held on Monday December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators

First Week of January 2017 Options Trading For TG Therapeutics (TGTX)

First Week of January 2017 Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.

TG Therapeutics Announces Positive DSMB Recommendation For Continuation Of The UNITY-CLL Phase 3 Trial

TG Therapeutics Announces Positive DSMB Recommendation For Continuation Of The UNITY-CLL Phase 3 Trial

No safety concerns identified; UNITY-CLL Phase 3 trial to continue as planned

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2016 Financial Results

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2016 Financial Results

Investor Conference Call to be Held Today, Monday, November 7, 2016 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2016 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2016 Financial Results And Business Update

Investor Conference Call to be held Monday, November 7, 2016 at 8:30am ET

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 58th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 58th American Society Of Hematology Annual Meeting

Investor Reception to be Held on Monday, December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators